Cost-Effectiveness Tool for Evaluating Interventions to Prevent Mother-to-Child Transmission - Manual and Model (UNAIDS, 2000, 94 p.): “ARV” WORKSHEET: (introduction...)

Cost-Effectiveness Tool for Evaluating Interventions to Prevent Mother-to-Child Transmission - Manual and Model (UNAIDS, 2000, 94 p.)

“ARV” WORKSHEET

		*(introduction...)*
		TABLE ARV-1: REGIMEN COMPONENTS
		TABLE ARV-2: GESTATIONAL AGE AT START OF TREATMENT
		TABLE ARV-3: MOTHERS AND CHILDREN RECEIVING VARIOUS SERVICE COMPONENTS
		TABLE ARV-4: DOSES, DRUGS AND DRUG COSTS.
		TABLE ARV-5: EFFECTIVENESS ESTIMATES
		TABLE ARV-6: ARV EFFECTIVENESS - ADJUSTMENTS FOR IMPERFECT ADHERENCE

(introduction...)

In this section, you will be presented with a description of the ARV regimens you wish to evaluate including their efficacies and dose patterns. The corresponding Excel spreadsheet is called “ARVs”.

The choice of ARVs, doses, timing of doses and estimated efficacy of these regimens are derived from clinical trials and are given by the model (blue cells). The trial-derived efficacy figures can then be adjusted to reflect imperfect adherence (relevant if you believe that adherence in your setting will be different from adherence in the trials); and late arrival for treatment (relevant for the three regimens with a prepartum component - ACTG 076; CDC-Thai; and PETRA-A). In addition, the user enters the cost of each dose to mother and to infant. Based on this cost data, the intended number of doses in the regimen, and the number of mothers who receive each component of the regimen, the model then calculates the drug costs per woman and annual drug costs for the expected number of women to be treated in the service area.